about
Microfluidic enrichment for the single cell analysis of circulating tumor cells.A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination.HPV-associated lung cancers: an international pooled analysis.Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells.Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis.'Prechronous' metastasis in clear cell renal cell carcinoma: a case reportMetronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer.Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules.Novel therapeutic targets on the horizon for lung cancer.A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancerMetronomic chemotherapy: A relook at its basis and rationale.First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009.Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.Phase II clinical trials in oncology: are we hitting the target?Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer.A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer.Advances in systemic treatment for nasopharyngeal carcinoma.An ultra-high-throughput spiral microfluidic biochip for the enrichment of circulating tumor cells.Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-ExpansiInteractions between clinical factors, p16, and cyclin-D1 expression and survival outcomes in oropharyngeal and hypopharyngeal squamous cell carcinoma.Correlation between epidermal growth factor receptor mutations and expression of female hormone receptors in East-Asian lung adenocarcinomas.Trajectory and risk factors for chemotherapy-induced nausea and vomiting in Asian patients with head and neck cancer.Should screening for DPD deficiency be mandatory before 5-FU exposure?A phase II trial of induction gemcitabine and vinorelbine followed by concurrent vinorelbine and radiotherapy in locally advanced non-small cell lung cancer.A Phase I trial of weekly docetaxel and topotecan for solid tumors.An extracellular matrix-related prognostic and predictive indicator for early-stage non-small cell lung cancer.Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma.Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients.EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients.Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.A Decade of Never-smokers Among Lung Cancer Patients-Increasing Trend and Improved Survival.Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma.Reply: the BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia.Differences between small-cell lung cancer and non-small-cell lung cancer among tobacco smokersA randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderlyParaneoplastic pemphigus resembling linear IgA bullous dermatosis
P50
Q27340255-2C54120C-9931-4696-A780-523147A81303Q27851729-441AC9C8-3C50-49BC-B271-78508D4995FFQ33364221-5CD545D7-0A7B-47DC-BBF9-04CDB1EB078CQ33705253-89522699-FCBB-4F9F-B056-BF7CC8D361FEQ33856619-DA6887C0-B0CC-43B0-9081-508227B656F5Q34397588-5A9D2BA3-1BE4-4C1E-AC83-044388C22B25Q35025318-E4A17474-028C-40C8-94E3-4A1701C33EA0Q35610404-1798BE39-93AD-4583-89A6-2AA6432DC6D6Q36005030-762D79D5-12A6-4918-9660-A3FE3F20CAD1Q36100771-B4F7ED5E-4D50-45EA-AE62-2EDAFCDED39CQ36201492-CBF70237-9115-4FFA-BFFF-F748E6141D80Q36230769-54C931DF-6EEF-4FD2-9D22-AC39BB9107F3Q37625444-466AD758-58E5-451A-BE61-F7DFCDD422EEQ37690437-FF46538B-7214-4E86-AEA5-4F06F77A14F4Q37705422-89F66C46-927B-47C8-89CE-BDD57EA3DFF5Q38385856-FC4EBFEC-E599-466A-B040-FFD2CF33323AQ38388127-2F7A1890-C732-4500-80F9-63AB171E55EEQ38430341-BD0D11EF-79DD-4886-8C3A-3A878C5CBB5FQ38806879-353845B8-328E-4A7A-B92D-72835AE51722Q38819380-7DD54AE8-524C-47A6-A323-C80FAD2C3470Q38993819-19082731-7B22-4501-BFB9-0D56F2A92348Q39168168-5ED4C6AD-9ECE-4B30-A10A-82E66F92D6F7Q42210776-E9032E22-0B39-4E48-A1BC-A306A2C6E620Q43252127-2BF9BC71-E65F-4CC1-A3A7-020263B043BAQ43959318-6309F0EA-0104-4F8F-9B14-BE9C8F420AB2Q45189579-0B12E3A2-36AD-4D8D-B13B-7DB04E359FC3Q45990206-66EA61A6-29A6-42EF-828D-0CE7747DC043Q46981461-0299F25E-E43E-4D3A-9FD7-04DBB09372DFQ47133382-C1D540D3-E776-4837-B986-FB8FCB1E7593Q48042302-9CA1C25C-14E2-496B-AF7A-4AA3995BB702Q50089508-8FFEB1C0-3AC1-4A64-B3C8-BFA9C92F2997Q51212794-FDFE06D0-4E64-40B0-852B-73EC03CFF3FCQ51291400-EEF14B83-EF8A-44AB-A5C4-BC52D25617CFQ52627357-7EB78275-11F4-4C53-B3A2-794B6FD765BAQ52720969-FD8032F0-0419-49BC-9EAB-7F8A856CF547Q53065761-B7BF166B-7846-4E30-87D2-C1EBC78F9BA0Q55070789-E65814FB-2B60-45D0-9586-1BE172F57085Q79707029-209070BE-1AE8-432F-A5A0-A2CC13F6B034Q80101163-3E66C9FC-6A54-466A-AD39-9D569B7903D5Q80232797-FCAC4D8B-8BF9-4D49-B93E-A63AF2267C79
P50
description
researcher, ORCID id # 0000-0002-4655-0206
@en
wetenschapper
@nl
name
Wan-Teck Lim
@ast
Wan-Teck Lim
@en
Wan-Teck Lim
@es
Wan-Teck Lim
@nl
type
label
Wan-Teck Lim
@ast
Wan-Teck Lim
@en
Wan-Teck Lim
@es
Wan-Teck Lim
@nl
prefLabel
Wan-Teck Lim
@ast
Wan-Teck Lim
@en
Wan-Teck Lim
@es
Wan-Teck Lim
@nl
P106
P1153
7202377447
P31
P496
0000-0002-4655-0206